By Jane Koo
The patient-specific nature of autologous cell therapies presents unique challenges that can best be addressed by a middle path between on-site and centralized manufacturing.
Read the full article here: BioSpace
The Medicine Maker 2026 Power List
Celebrating 60 inspirational individuals – across small molecules, biopharma, and cell and gene therapy – who are helping to translate pharma’s...